Balanced news tone
News Sentiment
CING sentiment intelligence
Cingulate Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.
Price is moving more forcefully than the current news tone suggests.
84/100 classification confidence.
directly relevant articles
high-authority source matches
-8.7% over one week, +0.6% over four weeks, trend inactive, and below fair value.
Cingulate Inc. Files 8-K with SEC: Key Corporate Details, Emerging Growth Status, and Nasdaq Listing Information
Market Reaction
Price moving ahead of tone
Price is moving more forcefully than the current news tone suggests.
Sentiment Mix
Positive, neutral, negative
Relevance
Why the article matched
Sources
Coverage mix
Event Lens
What the news is about
Sentiment Trail
Score over time
News Tape
Relevant headlines
FDA sends CRL on Cingulate (NASDAQ: CING) ADHD drug CTx-1301
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 02 Jun 2026 07:00
- Source
- Stock Titan
FDA declines to approve Cingulate's ADHD treatment over manufacturing issues
- Tone
- Negative 34/100
- Event
- Market update
- Published
- 02 Jun 2026 07:00
- Source
- Reuters
Cingulate stock reaffirmed at Buy by H.C. Wainwright ahead of FDA decision
- Tone
- Positive 66/100
- Event
- Market update
- Published
- 26 May 2026 07:00
- Source
- Investing.com
There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings
- Tone
- Negative 34/100
- Event
- Earnings
- Published
- 15 May 2026 07:00
- Source
- simplywall.st
Cingulate Inc. Reports First Quarter 2026 Financial Results and Provides an Update of Commercial Readiness Efforts On Track for lead ADHD Asset CTx-1301
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 14 May 2026 12:00
- Source
- GlobeNewswire
Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 14 May 2026 07:00
- Source
- Market source
Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results
- Tone
- Positive 66/100
- Event
- Earnings
- Published
- 11 May 2026 07:00
- Source
- simplywall.st
Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 11 May 2026 07:00
- Source
- Market source
Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 25 Apr 2026 07:00
- Source
- Market source
Here is Why Cingulate (CING) is One of the Best NASDAQ Growth Stocks to Buy and Hold Forever
- Tone
- Positive 82/100
- Event
- Market update
- Published
- 24 Apr 2026 07:00
- Source
- Market source
Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 21 Apr 2026 07:00
- Source
- Market source
Cingulate says its ADHD drug faces manufacturing review, not safety issues
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 06 Apr 2026 07:00
- Source
- Stock Titan
Stonegate Capital Partners Updates Coverage on Cingulate Inc. (CING) 4Q25
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 06 Apr 2026 07:00
- Source
- TMX Newsfile
A Look Back at Biotechnology Stocks’ Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 29 Mar 2026 07:00
- Source
- TradingView
Cingulate Inc. Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 18 Mar 2026 07:00
- Source
- Market source
Why did Cingulate stock skyrocket today?
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 16 Mar 2026 07:00
- Source
- Invezz
Cingulate Announces the Closing of a $12 Million Private Placement Priced At-the-Market Under Nasdaq Rules
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 17 Feb 2026 08:00
- Source
- Market source
Cingulate (NASDAQ: CING) Gains FDA Acceptance of CTx-1301 NDA, Eyes ADHD Launch
- Tone
- Positive 66/100
- Event
- Market update
- Published
- 18 Nov 2025 08:00
- Source
- Stock Titan
Cingulate (NASDAQ: CING) raises $6M, appoints Bryan Downey CCO; PDUFA May 2026
- Tone
- Positive 66/100
- Event
- Market update
- Published
- 13 Nov 2025 08:00
- Source
- Stock Titan
Cingulate (NASDAQ: CING) appoints CCO to drive CTx-1301 launch prep amid May 2026 PDUFA
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 10 Nov 2025 08:00
- Source
- Stock Titan